Dompé
at a glance

RESEARCH, DEVELOPMENT AND PRODUCTION

Dompé is a privately-owned global bio-pharmaceutical company with 130 years of experience.

PRIMARY CARE Outside the US

Prescription drugs and OTC products, dietary supplements, medical devices and cosmetics

BIOTECH

Treatment of rare diseases and conditions with high unmet need

We conduct research activities as part of a network of over 300 centers and universities around the globe.

Discover our research
Discover our production hub
head icon
GLOBAL THERAPEUTIC AREAS

Diabetes, Opthalmology, and conditions with high unmet need

globe icon
REACH

Europe, United States, China

people icon
800

More than 800 employees globally, including contractors and sales agents

boxes icon
60 MILLION

Packages manufactured in 2019

productionLine icon
8

Production lines

dnaBio icon
PARTNER

Small molecule and biotech production capabilities

certificate icon
BIOTECH APPROVALS

EMA (European Medicines Agency), Europe
FDA (Food and Drug Administration), United States

BIOTECH

Dompé developed the application of rhNGF (recombinant human Nerve Growth Factor) approved by the FDA and EMA.

  • 2017

    Marketing authorization granted by the EMA in addition to fast track and priority review designations by FDA

  • 2018

    FDA approval

  • 2019

    Chinese National Medical Products Administration (NMPA) inclusion among the 40 clinically needed drugs overseas

  • 2020

    Expected Chinese NMPA marketing authorization

Discover our biotech production
HISTORY

Dompé farmaceutici was established in 1940, growing from pharmaceutical roots in the Nineteenth Century

  • 1870-1890

    Gian Antonio Dompé devotes himself to studying chemical-pharmaceutical sciences and becomes a respected expert.

  • 1895

    Onorato Dompé, Gian Antonio’s son, establishes the Dompé-Adami laboratory.

  • 1924

    Onorato Dompé establishes the first pharmaceutical production plant in Milan.

  • 1940

    Franco Dompé, founds Dompé farmaceutici.

Discover our full story